Kyoto University

Sumitomo Dainippon Pharma Co., Ltd.

Ajinomoto Co., Ltd.

Takeda Pharmaceutical Company Limited

Makoto Ikeya

Junya Toguchida

Kyosuke Hino

Tsuyoshi Kobayashi

Sho Senda

Ikue Harata

Hidetoshi Sakurai

Koji Yokoyama

Toshio Heike

Knut Woltjen

Ryuta Nishikomori

Yayoi Kamiya

Taiki Nakajima

Akihito Tanaka

Hiroki Ozawa

Yonghui Jin

Akira Ohta

Provided is a method of producing a somite cell from a pluripotent stem cell, comprising the step of culturing a pluripotent stem cell in a medium comprising a GSK3β inhibitor. Provided is a method of producing a dermatome cell from a somite cell, comprising the step of culturing a somite cell in a medium comprising a GSK3β inhibitor and BMP. Provided is a method of producing a syndetome cell from a sclerotome cell, comprising the steps of culturing a sclerotome cell in a medium comprising FGF and then culturing the cell in a medium comprising BMP and TGFβ. Provided is a method of producing a mesenchymal stromal cell from a somite cell, comprising the step of culturing a somite cell in a medium comprising FGF. Provided are methods of producing a myotome cell, a dermatome cell, a sclerotome cell, and a syndetome cell from a pluripotent stem cell through a somite cell by appropriately combining the above methods and known methods.

Stepwise method of producing various types of cells from pluripotent stem cells

As a technique for proliferating neural crest cells without reducing differentiation capacity, provided is a method for producing neural crest cells, comprising the steps of: (1) obtaining neural crest cells; and (2) suspension-culturing the neural crest cells in a medium comprising a GSK3β inhibitor and a basic fibroblast growth factor (bFGF), wherein the medium comprises the GSK3β inhibitor with a concentration that exhibits an effect equivalent to that exhibited by CHIR99021 with a concentration of higher than 1 μM and lower than 5 μM.

Method for culture of cells

The present invention relates to a prophylactic or therapeutic agent for fibrodysplasia ossificans progressiva comprising as an active ingredient, at least one compound selected from the group consisting of rapamycin, temsirolimus, everolimus, ridaforolimus, TAFA93, umirolimus, olcorolimus, zotarolimus, and pharmaceutically acceptable salts thereof.

Therapeutic agent for fibrodysplasia ossificans progressiva

Mesenchymal stem cells may be culture for a long period, without using any special apparatus, equipment and the like, in a medium in which seven kinds of nonessential amino acids of glycine, alanine, serine, proline, asparagine, aspartic acid, and glutamic acid are reduced.

Culture medium for mesenchymal stem cells

The invention provides a prophylactic agent or therapeutic agent for fibrodysplasia ossificans progressiva, containing as an active ingredient a binding inhibitor that inhibits interaction between activin and activin A receptor type I (ACVR1), or an expression suppressor that suppresses expression of activin.

Prophylactic agent and therapeutic agent for fibrodysplasia ossificans progressiva

A method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia and a therapeutic and/or preventive drug for cartilaginous hyperplasia are provided. The following are provided: a method of screening for a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising a step of culturing chondroprogenitor cells under conditions in which the cells are brought into contact with a test substance and conditions in which the cells are not brought into contact with the test substance and a step of determining the SOX9 promoter activity, cAMP level, or degree of phosphorylation of CREB in the cells or the extracellular matrix volume in a culture; and a therapeutic and/or preventive drug for cartilaginous hyperplasia, comprising as an active ingredient an adenylate cyclase inhibitor.

Preventive and therapeutic drug for cartilaginous hyperplasia and method of screening for the same

The present invention provides a method of producing a skeletal muscle cell from a pluripotent stem cell, which includes a step of expressing one or more exogenous factors selected from MyoD, Myf5 and nucleic acids encoding them on a pluripotent stem cell.

Method of inducing differentiation from pluripotent stem cells to skeletal muscle cells

Growing community of inventors

Kyoto, Japan

Makoto Ikeya